Polyrizon Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 2.0
- Dividend yield
- –
About Polyrizon
Surgical & Medical Instruments & Apparatus, SIC 3841
Polyrizon Ltd. is a development-stage biotechnology company focused on designing and developing biopolymer-based products for medical and therapeutic uses. Its core development efforts center on its Capture and Contain (C&C) product candidates, including the PL-16 candidate, which create a physical barrier to block influenza and allergens from reaching the nasal epithelial tissue. The company also advances other product candidates utilizing its Trap and Target (T&T) platform technology designed for nasal delivery of active pharmaceutical ingredients (APIs). As a clinical-stage biotechnology firm, its technologies are targeted toward patient populations affected by airborne allergens, respiratory viral infections, and related conditions.
The company operates primarily out of Israel, with principal executive offices and facilities located in Raanana. Its ongoing operational scale centers on preclinical studies and clinical trial preparations, with corporate management and research activities coordinated from its Israeli headquarters.
Summary of the business section of Polyrizon's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Polyrizon Ltd.
- Headquarters
- Ra'Anana, Israel
- Address
- Hapnina St 8 4321545
- Phone
- 972-54-7979668
- Website
- polyrizon-biotech.com
- Employees
- 10, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Brightman Almagor Zohar & Co., Tel Aviv, Israel
Stock & identifiers
- Ticker
- PLRZ
- Exchange
- Nasdaq
- IPO date
- Oct 29, 2024
- Shares outstanding
- 2M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-6 reverse, Mar 25, 2026; 1-for-6 reverse, Nov 28, 2025; 1-for-250 reverse, May 27, 2025
- SEC CIK
- 1893645
- CUSIP
- M79549206
- ISIN
- USM795492067
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Tomer Izraeli | Chief Executive Officer, Director | 31,512 |
| Tidhar Turgeman | Chief Technology Officer, Director | 17,518 |
| Eyal S. Ron | Chief Science Officer | 1,459 |
| Nir BenYosef | Chief Financial Officer | 3 |
| Liron Carmel | Director | 3,127 |
| Oz Adler | Director | 19,850 |
| Liat Sidi | Director | 3,646 |
| Yehonatan Zalman Vinokur | Director | 3,646 |
| Asaf Itzhaik | Director | 3,646 |
Employees
Headcount reported in annual reports
“All directors and senior management as a group, consisting of 10 persons as of December 31, 2025”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 21, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |